274 related articles for article (PubMed ID: 10968495)
1. Changes in peak expiratory flow indices as a proxy for changes in bronchial hyperresponsiveness. Dutch Chronic Non-Specific Lung Disease study group.
Douma WR; Kerstjens HA; Roos CM; Koëter GH; Postma DS
Eur Respir J; 2000 Aug; 16(2):220-5. PubMed ID: 10968495
[TBL] [Abstract][Full Text] [Related]
2. Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group.
Brand PL; Duiverman EJ; Waalkens HJ; van Essen-Zandvliet EE; Kerrebijn KF
Thorax; 1999 Feb; 54(2):103-7. PubMed ID: 10325912
[TBL] [Abstract][Full Text] [Related]
3. Testing bronchial hyper-responsiveness: provocation or peak expiratory flow variability?
den Otter JJ; Reijnen GM; van den Bosch WJ; van Schayck CP; Molema J; van Weel C
Br J Gen Pract; 1997 Aug; 47(421):487-92. PubMed ID: 9302787
[TBL] [Abstract][Full Text] [Related]
4. Peak flow variation in childhood asthma: relationship to symptoms, atopy, airways obstruction and hyperresponsiveness. Dutch CNSLD Study Group.
Brand PL; Duiverman EJ; Postma DS; Waalkens HJ; Kerrebijn KF; van Essen-Zandvliet EE
Eur Respir J; 1997 Jun; 10(6):1242-7. PubMed ID: 9192923
[TBL] [Abstract][Full Text] [Related]
5. Which index of peak expiratory flow is most useful in the management of stable asthma?
Reddel HK; Salome CM; Peat JK; Woolcock AJ
Am J Respir Crit Care Med; 1995 May; 151(5):1320-5. PubMed ID: 7735580
[TBL] [Abstract][Full Text] [Related]
6. Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness.
Verhoeven GT; Hegmans JP; Mulder PG; Bogaard JM; Hoogsteden HC; Prins JB
Thorax; 2002 Aug; 57(8):694-700. PubMed ID: 12149529
[TBL] [Abstract][Full Text] [Related]
7. Influence of treatment on peak expiratory flow and its relation to airway hyperresponsiveness and symptoms. The Dutch CNSLD Study Group.
Kerstjens HA; Brand PL; de Jong PM; Koëter GH; Postma DS
Thorax; 1994 Nov; 49(11):1109-15. PubMed ID: 7831626
[TBL] [Abstract][Full Text] [Related]
8. PEF variability, bronchial responsiveness and their relation to allergy markers in a random population (20-70 yr).
Boezen HM; Postma DS; Schouten JP; Kerstjens HA; Rijcken B
Am J Respir Crit Care Med; 1996 Jul; 154(1):30-5. PubMed ID: 8680695
[TBL] [Abstract][Full Text] [Related]
9. Airway responsiveness to acetaldehyde in patients with asthma: relationship to methacholine responsiveness and peak expiratory flow variation.
Prieto L; Sánchez-Toril F; Brotons B; Soriano S; Casañ R; Belenguer JL
Clin Exp Allergy; 2000 Jan; 30(1):71-8. PubMed ID: 10606933
[TBL] [Abstract][Full Text] [Related]
10. Peak expiratory flow variability adjusted by forced expiratory volume in one second is a good index for airway responsiveness in asthmatics.
Matsunaga K; Kanda M; Hayata A; Yanagisawa S; Ichikawa T; Akamatsu K; Koarai A; Hirano T; Sugiura H; Minakata Y; Ichinose M
Intern Med; 2008; 47(12):1107-12. PubMed ID: 18552467
[TBL] [Abstract][Full Text] [Related]
11. Increased peak flow variability in children with asymptomatic hyperresponsiveness.
Gibson PG; Mattoli S; Sears MR; Dolovich J; Hargreave FE
Eur Respir J; 1995 Oct; 8(10):1731-5. PubMed ID: 8586130
[TBL] [Abstract][Full Text] [Related]
12. Mini-Wright peak flow meters are reliable after 5 years use. Dutch CNSLD Study Group.
Douma WR; van der Mark TW; Folgering HT; Kort E; Kerstjens HA; Koëter GH; Postma DS
Eur Respir J; 1997 Feb; 10(2):457-9. PubMed ID: 9042649
[TBL] [Abstract][Full Text] [Related]
13. Relationship between airway responsiveness and peak expiratory flow variability in subjects with allergic rhinitis.
Prieto L; Gutiérrez V; Bertó JM; Tornero C; Camps B; Pérez MJ
Ann Allergy Asthma Immunol; 1995 Sep; 75(3):273-9. PubMed ID: 7552931
[TBL] [Abstract][Full Text] [Related]
14. Fluticasone/formoterol association favors long-lasting decrease in bronchial reactivity to methacholine and weekly PEF variability.
Cortese S; Gatta A; Della Valle L; Mangifesta R; Di Giampaolo L; Cavallucci E; Petrarca C; Paganelli R; Di Gioacchino M
Int J Immunopathol Pharmacol; 2016 Dec; 29(4):769-774. PubMed ID: 27272161
[TBL] [Abstract][Full Text] [Related]
15. Peak flow lability: association with asthma and spirometry in an older cohort.
Enright PL; Burchette RJ; Peters JA; Lebowitz MD; McDonnell WF; Abbey DE
Chest; 1997 Oct; 112(4):895-901. PubMed ID: 9377950
[TBL] [Abstract][Full Text] [Related]
16. Peak expiratory flow variation and bronchial hyperresponsiveness in asthmatic children during periods of antigen avoidance and reexposure.
Valletta EA; Comis A; Del Col G; Spezia E; Boner AL
Allergy; 1995 Apr; 50(4):366-9. PubMed ID: 7573822
[TBL] [Abstract][Full Text] [Related]
17. Effects of single-dose zileuton on bronchial hyperresponsiveness in asthmatic patients treated with inhaled corticosteroids.
Dekhuijzen PN; Bootsma GP; Wielders PL; van den Berg LR; Festen J; van Herwaarden CL
Eur Respir J; 1997 Dec; 10(12):2749-53. PubMed ID: 9493655
[TBL] [Abstract][Full Text] [Related]
18. Comparison of bronchial reactivity and peak expiratory flow variability measurements for epidemiologic studies.
Higgins BG; Britton JR; Chinn S; Cooper S; Burney PG; Tattersfield AE
Am Rev Respir Dis; 1992 Mar; 145(3):588-93. PubMed ID: 1546839
[TBL] [Abstract][Full Text] [Related]
19. Relationship of airway hyperresponsiveness to respiratory symptoms and diurnal peak flow variation in patients with obstructive lung disease. The Dutch CNSLD Study Group.
Brand PL; Postma DS; Kerstjens HA; Koëter GH
Am Rev Respir Dis; 1991 May; 143(5 Pt 1):916-21. PubMed ID: 2024843
[TBL] [Abstract][Full Text] [Related]
20. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group.
FitzGerald JM; Chapman KR; Della Cioppa G; Stubbing D; Fairbarn MS; Till MD; Brambilla R
J Allergy Clin Immunol; 1999 Mar; 103(3 Pt 1):427-35. PubMed ID: 10069876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
